NDI-091143

Catalog No.S8878 Batch:S887801

Print

Technical Data

Formula

C20H14ClF2NO5S

Molecular Weight 453.84 CAS No. 2375840-87-0
Solubility (25°C)* In vitro DMSO 91 mg/mL (200.51 mM)
Ethanol 3 mg/mL (6.61 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description NDI-091143 is a potent inhibitor of human ATP-citrate lyase(ACLY) with a Ki of 7.0 nM and an IC50 of 2.1 nM in the ADP-Glo assay.
Targets
ATP-citrate lyase [1]
(Cell-free assay)
7.0 nM(Ki)
In vitro

ACLY inhibitor NDI091143 exerts dose-dependent inhibition of T24 and T24T clonogenic survival. [1]

Protocol (from reference)

Cell Assay:

[1]

  • Cell lines

    BCa cell lines (UMUC3, T24, T24T)

  • Concentrations

    5-100 μM

  • Incubation Time

    10–14 days

  • Method

    BCa cells are plated in wells of 6-well plates at a density of 500 cells/ well, and allowed to attach for 16 h, before being treated with NDI091143 for further 10–14 days. Formation of cell colonies > 50 cells/colony is confirmed by examination under inverted microscope. Plates are then fixed with 4% paraformaldehyde and are stained with crystal violet.

Selleck's NDI-091143 has been cited by 4 publications

Snail acetylation by autophagy-derived acetyl-coenzyme A promotes invasion and metastasis of KRAS-LKB1 co-mutated lung cancer cells [ Cancer Commun (Lond), 2022, 42(8):716-749] PubMed: 35838183
Snail acetylation by autophagy-derived acetyl-coenzyme A promotes invasion and metastasis of KRAS-LKB1 co-mutated lung cancer cells [ Cancer Commun (Lond), 2022, 10.1002/cac2.12332] PubMed: 35838183
ACLY inhibitors induce apoptosis and potentiate cytotoxic effects of sorafenib in thyroid cancer cells [ Endocrine, 2022, 10.1007/s12020-022-03124-6] PubMed: 35761130
Metabolomic credentialing of murine carcinogen-induced urothelial cancer [ Sci Rep, 2021, 11(1):22085] PubMed: 34764423

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.